RxSight, Inc.
RXST
$6.26
-$0.23-3.54%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -18.91% | -14.09% | -3.58% | 28.41% | 40.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -18.91% | -14.09% | -3.58% | 28.41% | 40.71% |
| Cost of Revenue | -35.72% | -39.44% | -20.59% | 8.37% | 4.58% |
| Gross Profit | -12.24% | -3.94% | 3.88% | 36.95% | 63.07% |
| SG&A Expenses | -2.09% | 6.78% | 19.28% | 22.77% | 33.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.03% | -4.54% | 10.23% | 20.87% | 23.86% |
| Operating Income | -31.40% | -32.00% | -68.04% | -0.04% | 20.49% |
| Income Before Tax | -54.35% | -55.04% | -93.86% | 10.11% | 35.55% |
| Income Tax Expenses | -58.33% | -23.08% | 100.00% | 100.00% | 166.67% |
| Earnings from Continuing Operations | -54.13% | -54.88% | -93.88% | 10.00% | 35.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -54.13% | -54.88% | -93.88% | 10.00% | 35.29% |
| EBIT | -31.40% | -32.00% | -68.04% | -0.04% | 20.49% |
| EBITDA | -29.25% | -39.92% | -75.75% | -3.59% | 17.22% |
| EPS Basic | -51.12% | -50.41% | -82.99% | 18.14% | 42.36% |
| Normalized Basic EPS | -51.20% | -50.50% | -83.05% | 18.22% | 42.55% |
| EPS Diluted | -51.12% | -50.41% | -82.99% | 18.14% | 42.36% |
| Normalized Diluted EPS | -51.20% | -50.50% | -83.05% | 18.22% | 42.55% |
| Average Basic Shares Outstanding | 2.03% | 2.96% | 5.95% | 9.95% | 12.22% |
| Average Diluted Shares Outstanding | 2.03% | 2.96% | 5.95% | 9.95% | 12.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |